EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Skin n Skin Co. Ltd (159910) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Skin n Skin Co. Ltd KRW 717, price KRW 3,020, upside -76.3%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Consumer Defensive · KR · ISIN KR7159910009

SN Thin data Sep 24, 2026

Skin n Skin Co. Ltd

159910 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 716.55 KRW · Strongly overvalued (−76%)
!Quality 42/100
!Weak Growth (revenue 5y −17.7 %/yr)
!Loss-making · -33.9% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (2/8)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

23,750 KRW 2,480 KRW Fair Value 716.55 KRW Jun 2019 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 2,480 KRW – 23,750 KRW · fair‑value band 472.92 KRW – 895.68 KRW · the 3,020 KRW price screens above the 716.55 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Skin n Skin Co. in your weekly email

Every Wednesday you see whether Skin n Skin Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

EcoGlow Co., Ltd. manufactures and distributes cosmetics and merchandise. It offers skin care products under the t-Timing brand; and beauty tea cafe under the a;t fox brand name. The company was formerly known as Skin n Skin Co., Ltd. and changed its name to EcoGlow Co., Ltd. in May 2025. EcoGlow Co., Ltd.

Show more

EcoGlow Co., Ltd. manufactures and distributes cosmetics and merchandise. It offers skin care products under the t-Timing brand; and beauty tea cafe under the a;t fox brand name. The company was formerly known as Skin n Skin Co., Ltd. and changed its name to EcoGlow Co., Ltd. in May 2025. EcoGlow Co., Ltd. was founded in 2006 and is headquartered in Paju-Si, South Korea.

Stock analysis

Skin n Skin Co. Ltd (159910) currently trades at 3,020 KRW, while our model-based Fair Value estimate is 716.55 KRW, implying the stock looks roughly 321.4% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 472.92 KRW (bear) to 895.68 KRW (bull), the price of 3,020 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Consumer Defensive sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Skin n Skin Co. Ltd reported revenue of 9.9B KRW in FY2025 versus 27.6B KRW in FY2021, a compound −22.6%/yr. Reported net income was −5.7B KRW in FY2025.

Key figures

Market cap 31.5B KRW (≈ $23.1M) · P/S ratio 2.90 · Net margin −57.2% · Return on equity −12.3% · Return on assets (EBIT) −16.9% · Operating margin −9.6% · Revenue (TTM) 11.2B KRW · Revenue growth (YoY) +37.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 34% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −14% fair-value upside, at −76%, 159910 screens richer than that median.

Fair Value models

Bear 472.92 KRW Fair Value 716.55 KRW Bull 895.68 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 945.37 KRW 1,267 KRW 1,891 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 945.37 KRW 1,267 KRW 1,891 KRW 54

Open the full fair value analysis →

Notify me when 159910 reaches fair value

Put 159910 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 42/100

Of which business quality 41 · Market factors (momentum, volatility) 35

Profitability 3
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 86
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 38
Price trend over the last 3–12 months (market factor)
52W Momentum 15
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−31.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.7%
Start year 2020 (pandemic). Over 10 years: −6.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−48.0% (2020) → −39.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

159910 screens 321% overvalued. Compare with Colgate-Palmolive Company →

Compare Skin n Skin Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 251 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −76% · Bottom 25%
Profitability
Return on assets −7% · Bottom 25%
Net margin (TTM) −34% · Bottom 25%
Operating margin (TTM) −10% · Bottom 25%
Growth and dividend
Revenue growth 38% · Top 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)100 · sector 8
PAST (return on equity)0 · sector 27
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 55

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Colgate-Palmolive Company CL $85.93 $55.95 −35%
Hindustan Unilever Limited HINDUNILVR ₹1,950 ₹775.25 −60%
Kenvue Inc KVUE $17.86 $12.73 −29%
Kimberly-Clark Corporation KMB $97.70 $83.93 −14%
Henkel AG HEN €68.50 €80.96 +18%
The Estée Lauder Companies Inc EL $98.83 $27.22 −72%
Church & Dwight Co CHD $96.02 $65.12 −32%
Beiersdorf Aktiengesellschaft, BEI €78.18 €68.95 −12%
Puig Brands, S.A PUIG €17.56 €19.32 +10%
The Clorox Company CLX $87.15 $104.53 +20%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Skin n Skin Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/159910

Frequently asked questions

Is Skin n Skin Co. Ltd (159910) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 716.55 KRW versus a price of 3,020 KRW, about −76% upside (overvalued).
What is the fair value of 159910?
Our model-based fair value for Skin n Skin Co. Ltd is 716.55 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,020 KRW.
What is the quality score of 159910?
Skin n Skin Co. Ltd has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Skin n Skin Co. Ltd (159910)?
Our model-based price target is the fair value of 716.55 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 472.92 KRW, optimistic scenario 895.68 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Skin n Skin Co. Ltd stock forecast for 2026?
Our models put fair value at 716.55 KRW, about −76% upside versus a price of 3,020 KRW (overvalued). Cautious scenario 472.92 KRW, optimistic scenario 895.68 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Skin n Skin Co. Ltd (159910)?
Skin n Skin Co. Ltd reported trailing-twelve-month revenue of about 11.2B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Skin n Skin Co. Ltd (159910)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Skin n Skin Co. Ltd it is 716.55 KRW per share (as of Sep 24, 2026), against a price of 3,020 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Skin n Skin Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 159910 trades above its calculated fair value: price 3,020 KRW, fair value 716.55 KRW, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 159910?
No. The price is what the market pays today (3,020 KRW); the fair value is what the company's own numbers justify (716.55 KRW). For Skin n Skin Co. Ltd the two are 2,303 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Skin n Skin Co. Ltd worth?
The market values Skin n Skin Co. Ltd at about 31.5B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,020 KRW; our models calculate a fair value of 716.55 KRW per share.
What do the bullish and bearish scenarios say about 159910?
Our models span a range for Skin n Skin Co. Ltd: cautious scenario 472.92 KRW, base 716.55 KRW, optimistic 895.68 KRW per share (as of Sep 24, 2026, price 3,020 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Skin n Skin Co. Ltd (159910)?
Balance-sheet figures for Skin n Skin Co. Ltd (as of Sep 24, 2026): return on equity −12.3%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 159910 from its 52-week high?
Skin n Skin Co. Ltd trades at 3,020 KRW, about 34% below its 52-week high of 4,585 KRW and 22% above the low of 2,480 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 716.55 KRW is for.
Which stocks are comparable to Skin n Skin Co. Ltd?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, Kimberly-Clark Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Skin n Skin Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 3,020 KRW, calculated fair value 716.55 KRW (−76%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 159910 calculated?
We run Skin n Skin Co. Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 716.55 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Skin n Skin Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Skin n Skin Co. Ltd (159910)?
The closing price on Sep 23, 2026 was 3,020 KRW. Our model-based fair value is 716.55 KRW, about −76% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Skin n Skin Co. Ltd right now?
The price sits above even our optimistic bull case (895.68 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (472.92 KRW to 895.68 KRW) leaves room in how you read the outcome.

Key figures of Skin n Skin Co. Ltd

How large is the market capitalisation of Skin n Skin Co. Ltd (159910)?
The market capitalisation of Skin n Skin Co. Ltd is 31.5B KRW (≈ $23.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Skin n Skin Co. Ltd (159910)?
The price-to-sales ratio of Skin n Skin Co. Ltd is 2.90 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Skin n Skin Co. Ltd (159910)?
The net margin of Skin n Skin Co. Ltd is −57.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Skin n Skin Co. Ltd (159910)?
The return on equity (ROE) of Skin n Skin Co. Ltd is −12.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Skin n Skin Co. Ltd (159910)?
On an EBIT basis the return on assets of Skin n Skin Co. Ltd is −16.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Skin n Skin Co. Ltd (159910)?
The operating margin of Skin n Skin Co. Ltd is −9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Skin n Skin Co. Ltd (159910)?
Revenue at Skin n Skin Co. Ltd is growing +37.8% versus a year earlier (3y avg −9.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Skin n Skin Co. Ltd (159910) generate?
The free cash flow of Skin n Skin Co. Ltd is −5.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Skin n Skin Co. Ltd (159910) carry?
The net debt of Skin n Skin Co. Ltd is 592M KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Skin n Skin Co. Ltd in the live analysis

One click puts Skin n Skin Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.